ASH 2022 | Results from the first-in-human trial of TG-1801 in patients with B-cell lymphoma
In this video, Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, comments on the first-in-human trial of TG-1801, a bispecific antibody targeting CD19 and CD47, in patients with B-cell lymphoma. Dr Cheah first explains the mechanism of action of this agent, and then goes on to discuss results from this trial. TG-1801 monotherapy had reasonable activity, particularly in patients with indolent lymphoma subtypes; however, there was improved efficacy and greater reduction in tumor burden for both aggressive and indolent lymphomas when TG-1801 was combined with ublituximab. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Consultancy, Honoraria; TG Therapeutics: Consultancy, Honoraria; Eli Lilly and Company: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria; Merck Sharp & Dohme: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding.
